Assessment of Beta-Blocker Treatment in Japanese Patients with Chronic Heart Failure

Not Applicable

• Conditions: Chronic heart failure

• Registration Number: JPRN-UMIN000000548
• Lead Sponsor: J-CHF Study Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-12-13
• Study Completion: 2009-12-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 480

Inclusion Criteria

Not provided

Exclusion Criteria

1) Primary illness of valvular stenosis, or severe valvular regurgitation. 2) Hypertrophic occlusive cardiomyopathy, restrictive cardiomyopathy, right ventricular cardiomyopathy of arrhythmic origin, or progressive myocarditis 3) Cardiogenic shock patients or patients with systolic blood pressure less than 80mmHg. 4) Severe arrhythmia, bradycardia (>=50 beats/min), or second-degree or higher atrioventricular block. However, cases of temporary bradycardia and Wenckebach second-degree atrioventricular block left to the judgment of the treating physician. 5) Acute myocardial infarction within 3 months prior to the date of consent. 6) Unstable angina pectoris or coronary spasm/rest angina. 7) CABG or PCI within 3 months prior to the date of consent, or patients scheduled for CABG or PCI during the study period. 8) Cerebrovascular accident within 6 months prior to the date of consent. 9) Bronchial asthma or other such chronic respiratory illness, or cor pulmonale. 10) History of malignant tumor or other such life-threatening illness of poor prognosis within 5 years prior to the date of consent. 11) Arteriosclerosis obliterans patients (Fontaine Class 2 or higher). 12) Poorly controlled diabetes. 13) Severe complication by any of the following illnesses: kidney disease , liver disease , anemia. 14) Thyroid dysfunction poorly controlled by treatment. 15) Pregnant, lactating, or possibly pregnant or desiring to become pregnant during the study period. 16) History of drug hypersensitivity to carvedilol. 17) Carvedilol administration is deemed contraindicated. 18) Written consent is not obtained. 19) Other patients deemed unsuitable as subjects of the study by the treating physician.

Study & Design

• Study Type: Interventional
• Study Design: Not specified